TIL (Instil Bio Inc.) Annual Net Income

Official company branding of instilbio.com (TIL)

Instil Bio, Inc. (TIL) specializes in developing innovative oncology treatments through genetic modification. Instil Bio, Inc. (TIL) creates a unique environment where individual lymphocytes are transformed into a targeted weapon against the disease. This price chart on GURU.Markets shows that the current figure is -0.03. The stability of scientific research is ensured by the isolation of US biotech clusters from global trade conflicts.

Net Income: Instil Bio Inc (TIL) for 07/04/2022 - 10/29/2026

Financial and market metric breakdowns for Instil Bio (TIL)

- stock value and consensus price forecast:
Market Price Instil Bio Inc|TIL - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization Instil Bio Inc|TIL - Real Price to Acquire Entire Company
- book value of equity indicators:
Net Asset Value per Share Instil Bio|TIL - Company Net Assets|Market Value to Book Value instilbio.com|TIL - Company Total Assets
- debt and solvency information:
Total Debt to Equity Ratio Instil Bio, Inc.|TIL - Long-Term Debt to Capital|Current Liabilities to Capital Instil Bio Inc.|TIL - Company Debts|Debt to Book Capitalization Ratio Instil Bio Inc|TIL - Company Long-Term Debt|Company Short-Term Debt Instil Bio|Intermediate Coverage Ratio instilbio.com
- company profitability and valuation multiples indicators:
TIL - Net Profit
Basic company analysis:Instil Bio Inc, TIL
Core merchandise of Instil Bio, Inc.

This indicator reflects the market consensus regarding daily net profit and the fundamental value of the business. Rising values confirm asset efficiency, while sharp spikes signal the risk of overpaying for the asset. By analyzing the company's net income metric, an investor assesses the real financial return. For Instil Bio, Inc. (TIL), this trend is critically dependent on the stability of the biotechnology sector. Geopolitical restrictions and data localization laws directly impact the final yield.

Main competitors

Company Net Income Legend Biotech Corp. (LEGN)|SANA (Sana Biotechnology) - Net Profit|AUTL - Annual Net Income|Net Income ALLO (Allogene)|RNAC - Company Net Income|Cellectis - Net Income|Final Profit CRBU|Genenta - Net Profit|Century Therapeutics (IPSC) - Net Income|JSPR: Net Profit|Company Net Income Senti Biosciences (SNTI)|Company Net Income Adaptimmune Therapeutics plc|Company Net Income CERO|Company Net Income Alaunos Therapeutics (TCRT)|Company Net Income ACHL (achillestx.com)|CARGO Therapeutics, Inc. - Net Income|Final Profit PSTX|2seventy Bio - Net Profit|Annual Net Income Gracell (GRCL)